Phase 3 Readout~month

Phase 3 Topline: An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients Wit

Indication
Severe Hypertriglyceridemia

Other upcoming events for IONS

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa
PDUFA DatePDUFA Date: zilganersen
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of
Phase 3 ReadoutPhase 3 Topline: An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familia
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Fami

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients Wit — IONS Phase 3 Readout | BioSniper